Vaccination in Sickle Cell Disease
Individuals with sickle cell disease require an enhanced vaccination schedule beyond routine immunizations, with particular emphasis on pneumococcal, meningococcal, Haemophilus influenzae type b, and annual influenza vaccines to prevent life-threatening infections from encapsulated bacteria.
Core Vaccination Requirements
Pneumococcal Vaccination (Critical Priority)
All patients with sickle cell disease aged ≥2 years must receive PCV13 (or newer formulations PCV15/PCV20) followed by PPSV23 at least 8 weeks later, with PPSV23 repeated every 5 years 1. For children under 2 years, complete the full 4-dose pneumococcal conjugate vaccine series with the most current formulation (currently PCV20 is approved starting at 6 weeks of age) 2.
The 2023 CDC recommendations specify:
- Children <6 years: Complete PCV series (PCV15 or PCV20) with catch-up dosing through 71 months
- Children 6-18 years who completed PCV before age 6: If at least one dose was PCV20, no additional doses needed. If only PCV13 or PCV15 was given, administer one dose of PCV20 or PPSV23
- Children 6-18 years never vaccinated: Single dose of PCV15 or PCV20; if PCV15 used, follow with PPSV23 at least 8 weeks later 3
Critical caveat: Research demonstrates that only 36% of patients maintain protective antibody levels 3 years post-vaccination 4, and seroprotection significantly declines after age 5 5. This suggests current 5-year booster intervals may be inadequate, though guidelines have not yet adjusted for this finding.
Meningococcal Vaccination (Mandatory)
Administer meningococcal vaccine starting at age ≥2 months, with revaccination every 5 years 1. The specific approach:
- MCV4 (conjugate vaccine against serotypes A, C, W, Y) given at young age
- Serogroup B vaccine administered after age 10 years 3
- Do NOT use MCV4-D in children <2 years due to reduced antibody response to pneumococcal serotypes when co-administered with PCV 1
Haemophilus influenzae Type b (Hib)
One dose of Hib vaccine is required for all unvaccinated persons aged ≥5 years with sickle cell disease 1, 6. This is beyond routine childhood schedules and specifically addresses functional asplenia.
Annual Influenza Vaccination
Annual inactivated influenza vaccine is strongly recommended 1, 2. Live attenuated influenza vaccine (LAIV) should NOT be used 1. Research shows influenza vaccination rates average only 69.5% in children with SCD, with higher compliance in younger children 7.
Routine Immunizations
All standard childhood and adult vaccines recommended by CDC/ACIP should be administered on schedule 1, 2. No routine vaccines are contraindicated except LAIV 1. This includes:
- Hepatitis A and B vaccines
- MMR (measles, mumps, rubella)
- Varicella
- Tdap/Td boosters
- HPV vaccine (age-appropriate)
The primary care physician should ideally administer these, with oversight and support from the sickle cell center 2.
Timing Considerations
Optimal Vaccination Windows
- Before starting disease-modifying therapy: Vaccines administered before hydroxyurea or other immunosuppressive treatments generate better immune responses 8
- Avoid vaccination <2 weeks before, during, or up to 3-6 months after chemotherapy due to poor response probability 8
- If receiving anti-CD20 antibodies: Postpone vaccinations 6-12 months from last dose for optimal serological response, though inactivated vaccines remain safe to give earlier 8
Special Populations
Premature infants: Initiate antibiotic prophylaxis (not vaccination) at 39 weeks corrected gestational age when taking full enteral feeds or at hospital discharge 2.
Implementation Strategy
Coordination of Care
- Newborn screening follow-up: Ensure notification reaches primary physician, parents, and designated SCD center 2
- First visit by 2 months of age: Confirm diagnosis, initiate penicillin prophylaxis, provide education 2
- Vaccination verification: SCD center should review and support vaccination status even when PCP administers vaccines 2
- Visit frequency:
- First year: Every 3-4 months minimum
- Second year: Every 3 months for severe phenotypes, minimum twice yearly for milder phenotypes
- All ages: At least annual comprehensive visit 2
Documentation Requirements
Perform extended red cell phenotype (all patients) and genotype (preferred) before first transfusion 2. This is critical for future transfusion management but doesn't directly affect vaccination schedules.
Common Pitfalls to Avoid
Stopping penicillin prophylaxis at age 5 without ensuring adequate vaccine immunity: Many providers discontinue prophylaxis at this age, but research shows vaccine protection often wanes by then 4
Missing SCD-specific vaccines: Studies show 21.8% of children with completed PCV7 series never received PPSV23, and 29.1% missed PCV13 doses 9. The vaccines specifically for encapsulated bacteria are most frequently delayed or missed 7
Assuming vaccination status is adequate: Only 44% of children in one study received appropriate booster doses 5. Active monitoring is essential.
Co-administering MCV4-D with PCV in children <2 years: This reduces pneumococcal antibody response 1
Using live vaccines inappropriately: LAIV is contraindicated; other live vaccines are generally safe unless patient is on significant immunosuppression 1
Monitoring and Boosters
While not yet standard practice, consider checking antipneumococcal antibody titers in high-risk patients, as research demonstrates significant loss of protection before the recommended 5-year booster interval 4. A Kaplan-Meier analysis revealed significant decline in seroprotection after age 5 following completion of the primary series 5, suggesting boosters may be needed sooner than current guidelines recommend.
The evidence strongly supports that functional asplenia in sickle cell disease creates lifelong vulnerability to encapsulated bacterial infections, making vaccination adherence critical for reducing morbidity and mortality 1, 10. The 93% reduction in invasive pneumococcal disease in children with SCD after PCV7 implementation demonstrates the life-saving impact of appropriate vaccination 1.